Tailoring combinatorial cancer therapies to target the origins of adaptive resistance

被引：8
|
作者：
Goldman, Aaron [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Biomed Engn, Cambridge, MA 02115 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2016年 / 3卷 / 01期
关键词：
adaptive resistance; tumor heterogeneity; cancer stem cells; mathematical modeling; computational biology;
D O I：
10.1080/23723556.2015.1030534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The development of resistance to chemotherapy is a critical yet poorly understood phenomenon driving cancer-related deaths. We recently reported a study that explored the origins of adaptive chemotherapy resistance. During this investigation we unexpectedly discovered that inherent vulnerabilities were unmasked, creating temporal targets for rational combinations of established drugs.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Target on molecular therapies in lung cancer
    Le Guen, Y
    Sabatier, L
    Le Chevalier, T
    Soria, JC
    BULLETIN DU CANCER, 2003, 90 (12) : 1055 - 1061
  • [22] The origins, roles and therapies of cancer associated fibroblast in liver cancer
    Zulaziz, Natasha
    Chai, San Jiun
    Lim, Kue Peng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] Evaluation of ChatGPT's Potential in Tailoring Gynecological Cancer Therapies
    Krueckel, Annika
    Brueckner, Lena
    Psilopatis, Iason
    Fasching, Peter a.
    Beckmann, Matthias w.
    Emons, Julius
    IN VIVO, 2024, 38 (04): : 1649 - 1659
  • [24] Tailoring therapies to counter the divergent immune landscapes of breast cancer
    Attalla, Sherif
    Taifour, Tarek
    Muller, William
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [25] Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas
    Lo, Roger S.
    PHARMACOGENOMICS, 2012, 13 (02) : 125 - 128
  • [26] Effect of target therapies in liver cancer PDX tumor models: Response, resistance and predictive biomarkers
    Yu, Tengfei
    Yan, Ying
    Du, Wei
    Hua, Liang
    Yang, Xuqin
    Tan, Tingting
    Gu, Jiali
    Jiang, Jingjing
    Ye, Xin K.
    Gu, Zhenyu
    CANCER RESEARCH, 2015, 75
  • [27] Targeted therapies for prostate cancer: Strategies for efficient combinatorial approaches
    Butt, Nasir A.
    Dhar, Swati
    Kumar, Avinash
    Rimando, Agnes M.
    Zhang, Xu
    Levenson, Anait S.
    CANCER RESEARCH, 2016, 76
  • [28] Combinatorial therapies of neratinib for HER2-amplified cancer
    Zhao, Ming
    Scott, Stephen
    Evans, Kurt
    Yuca, Erkan
    Saridogan, Turcin
    Demirhan, Mehmet E.
    Kirby, Bryce P.
    Kopetz, Scott
    Diala, Irmina
    Lalani, Alshad S.
    Piha-Paul, Sarina A.
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [29] Synthetic lethal screening: A pathway for rational combinatorial therapies for cancer
    Axelrod, Mark J.
    Gioeli, Daniel G.
    Weber, Michael J.
    CANCER RESEARCH, 2012, 72
  • [30] Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
    Laetitia, Gheysen
    Sven, Saussez
    Fabrice, Journe
    CELLS, 2020, 9 (04)
12345